Bridging the Gap Between Lab and Life
PROF. DR. DIPANJAN PAN
CTO, CO-FOUNDER & ACADEMIC PROFESSOR,
Bridging AI and the Arts to Build a Better Tomorrow
PROF. DR. DIPANJAN PAN
Dean of Academic Technology
ECPI University
In a world where millions still die waiting for blood in ambulances, for early diagnoses, for treatments science hasn’t yet delivered, innovation in healthcare remains both urgent and uneven. The problem isn’t a lack of ideas, but the gap between discovery and deployment. Bridging that gap is where Prof. Dipanjan Pan thrives. A scientist, entrepreneur, and educator, he has dedicated his career to translating complex research into life-saving solutions. As the Dorothy Foehr Huck & J. Lloyd Huck Endowed Chair Professor in Nanomedicine at the Pennsylvania State University, and the cofounder of startups like KaloCyte, VitruVian Bio, and Innsight Tech, he has pioneered synthetic blood substitutes, tear-based diagnostics, targeted nanomedicine therapies and point-ofcare infectious disease diagnostics. With over two decades of academic leadership—from Washington University and the University of Illinois to Penn State—his journey reflects a rare blend of compassion and complexity.
What inspired your move from research to building startups, and what were the toughest hurdles?
The transition didn’t happen overnight. The more time I spent in academic research, the more I felt the urge to push ideas beyond publications—to make a tangible difference in people’s lives. That’s what drew me to translational research. It’s the bridge between groundbreaking discoveries and real-world impact. I’ve always believed that research should improve human health. That belief led me to focus on speeding up the path from lab to clinic—from diagnostics to therapies. But the shift brought significant challenges: technical validation, human trials, market acceptance, securing capital, and most critically, building a crossfunctional team that could turn theory into scalable, regulatory-compliant products. Each challenge tested the vision, but they also made the outcomes far more meaningful.
How do you build tech roadmaps that are both cutting-edge and clinically relevant?
Serving as a CTO while also holding an academic role means I’m constantly straddling two fast-evolving worlds. My first step in building any roadmap is to understand the clinical challenge. That means engaging early with physicians, end-users, and stakeholders to align our innovations with real unmet needs. Staying current is non-negotiable. I regularly serve as an expert on scientific boards and review panels for the National Science Foundation, National Institute of Health, and Department of Defense. I collaborate with innovation hubs and speak at international conferences. This helps me stay ahead of what’s next—AI, smart materials, new delivery systems. Importantly, I don’t do this alone. For all my startups, we adopt a phased, team-driven approach. We validate ideas with pilot projects, adjust based on emerging evidence, and design with both scalability and regulatory compliance in mind. Innovation is only impactful when it’s paired with relevance and readiness.
What’s a common myth about nanomedicine you often have to debunk?
People often think nanomedicine is some futuristic invention, but it has ancient roots. The Egyptians used nanoscale gold, and Ayurvedic medicine used metallic powders like bhasma, which we now understand had nanoscale properties. One myth I frequently address is that nanotechnology is a brand-new, onedimensional field. In reality, it’s deeply interdisciplinary and built on decades—even centuries—of knowledge. Nanotechnology doesn’t offer simple fixes to complex problems—it demands rigorous research, experimentation, and precision. And despite fears, it’s not inherently dangerous. In fact, over 50 nanomedicine drugs are already approved for human use, with many more in clinical trials.
You operate in a rare intersection of nanomedicine, engineering, and innovation. How do you balance depth in research with the agility required of a tech leader?
Working at the intersection of basic science, engineering, and innovation means I’m constantly shifting gears— and I love that. My goal has always been to make a real and immediate impact on human lives, which is why translational research drives me. I build multidisciplinary teams—chemists, biologists, engineers—to keep the research depth while aligning with real-world needs. I lean on rapid prototyping and data-driven iteration to stay agile. To me, rigorous research and fast execution aren’t opposites—they’re partners in progress.
What’s a surprising lesson that helped shape your company’s success?
I’ve been involved in founding or co-founding five start ups. Founding these entities taught me that even the most groundbreaking ideas can stall if you don’t understand the path ahead. One is transforming eye exams with tearbased diagnostics, the other is creating synthetic blood for trauma care—two completely different missions. But the surprising insight? Innovation isn’t enough.
Understanding and appreciating the long, complex regulatory process of bringing a product to market was the greatest lesson I learned
It’s not glamorous, but that knowledge shaped how we plan, build, and push forward—because brilliant science only matters if it reaches the people who need it.
What’s one surprising synergy across your roles as professor, founder, editor, and CTO?
Honestly, switching roles so often taught me one
big thing: complexity only works if you can make it
simple. Whether teaching, building companies, editing
research, or leading tech teams, I rely on one core skill—
synthesizing complex ideas and communicating them
effectively. That’s the real glue across disciplines. It helps
people collaborate, innovate, and solve problems that
one perspective alone can’t crack.
Featured Magazine -
